Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. Gergis U, et al. Biol Blood Marrow Transplant. 2013 Jul;19(7):1040-5. doi: 10.1016/j.bbmt.2013.04.013. Epub 2013 May 4. Biol Blood Marrow Transplant. 2013. PMID: 23648237 Free article. Clinical Trial.
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Gergis U, et al. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):297-303. doi: 10.1016/j.clml.2016.02.004. Epub 2016 Feb 18. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27025789
Adoptive Immunotherapy with Cord Blood for the Treatment of Refractory Acute Myelogenous Leukemia: Feasibility, Safety, and Preliminary Outcomes.
Gergis U, Frenet EM, Shore T, Mayer S, Phillips A, Hsu JM, Roboz G, Ritchie E, Scandura J, Lee S, Desai P, Samuel M, Ball J, Blanco A, Romeo C, Albano MS, Dobrila L, Scaradavou A, van Besien K. Gergis U, et al. Biol Blood Marrow Transplant. 2019 Mar;25(3):466-473. doi: 10.1016/j.bbmt.2018.11.002. Epub 2018 Nov 9. Biol Blood Marrow Transplant. 2019. PMID: 30414955 Free article.
Hematology and oncology clinical care during the coronavirus disease 2019 pandemic.
Shah MA, Emlen MF, Shore T, Mayer S, Leonard JP, Rossi A, Martin P, Ritchie E, Niesvizky R, Pastore R, Cigler T, De Sancho M, Scheff R, Van Besien K, Roboz G, Nanus D, Goldstein P, Scrimenti L, Hidalgo M. Shah MA, et al. CA Cancer J Clin. 2020 Sep;70(5):349-354. doi: 10.3322/caac.21627. Epub 2020 Jul 14. CA Cancer J Clin. 2020. PMID: 32662880 Free PMC article.
Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response.
Chaekal OK, Scaradavou A, Masson Frenet E, Albano MS, Cushing M, Desai P, Dobrila L, Gergis U, Guarneri D, Hsu JM, Lee S, Mayer SA, Phillips AA, Orfali N, Ritchie EK, Roboz GJ, Romeo C, Samuel MS, Shore T, van Besien K. Chaekal OK, et al. Among authors: ritchie ek. Blood Adv. 2020 Oct 27;4(20):5146-5156. doi: 10.1182/bloodadvances.2020002805. Blood Adv. 2020. PMID: 33091124 Free PMC article.
Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors).
Ghalehsari N, Castillo Tokumori F, Chen Z, Liu M, Mayer SA, Zeinah GA, Shore TB, Ritchie EK, Silver RT, Scandura JM, Roboz GJ, van Besien K, Gomez-Arteaga A. Ghalehsari N, et al. Among authors: ritchie ek. Transplant Cell Ther. 2024 Nov;30(11):1100.e1-1100.e11. doi: 10.1016/j.jtct.2024.08.023. Epub 2024 Sep 5. Transplant Cell Ther. 2024. PMID: 39243817
91 results